Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients

Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients

Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients

Hospitalized COVID-19 sufferers usually current with a big spectrum of scientific signs. There’s a vital want to raised perceive the immune responses to SARS-CoV-2 that result in both decision or exacerbation of the scientific illness. Right here, we study longitudinal plasma samples from hospitalized COVID-19 sufferers with differential scientific consequence. We carry out immune-repertoire evaluation together with cytokine, hACE2-receptor inhibition, neutralization titers, antibody epitope repertoire, antibody kinetics, antibody isotype and antibody affinity maturation towards the SARS-CoV-2 prefusion spike protein.

Deadly circumstances reveal excessive plasma ranges of IL-6, IL-8, TNFα, and MCP-1, and sustained excessive share of IgA-binding antibodies to prefusion spike in contrast with non-ICU survivors. Illness decision in non-ICU and ICU sufferers associates with antibody binding to the receptor binding motif and fusion peptide, and antibody affinity maturation to SARS-CoV-2 prefusion spike protein. Right here, we offer perception into the immune parameters related to scientific illness severity and disease-resolution consequence in hospitalized sufferers that would inform improvement of vaccine/therapeutics towards COVID-19.

Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based evaluation

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are systemic necrotizing vasculitides related to important morbidity and mortality. Given the immunosuppression used to handle these situations, it will be important for clinicians to acknowledge issues, particularly infectious ones, which can come up throughout therapy. Kaposi sarcoma (KS) is a lymphoangioproliferative neoplasm attributable to human herpes virus 8 (HHV-8). Its cutaneous manifestations can mimic vasculitis.

We describe a 77-year-old man with microscopic polyangiitis with pulmonary-renal syndrome handled with prednisone and intravenous cyclophosphamide who developed KS (HHV-Eight constructive) after 2 months of therapy. Cyclophosphamide was discontinued and prednisone step by step lowered with enchancment and scientific stabilization of KS lesions.

This complete evaluation contains all revealed circumstances of KS in sufferers with AAV, with a aim to summarize potential danger components together with the scientific traits of vasculitis, therapy and outcomes of sufferers with this uncommon complication of immunosuppressive remedy. We additionally expanded our literature evaluation to KS in different types of systemic vasculitis. Our case-based evaluation emphasizes the significance of contemplating infectious issues of immunosuppressive remedy, particularly glucocorticoids, and highlights the uncommon affiliation of KS in systemic vasculitis.

Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients

Aggressive Immunoassay of SARS-CoV-2 Utilizing Pig Sera-Derived Anti-SARS-CoV-2 Antibodies

Anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) nucleoprotein (NP) antibodies have been remoted from pig sera utilizing human SARS-CoV-2 NP-immobilized magnetic beads. The binding properties of the remoted antibodies towards SARS-CoV-2 NP have been examined by way of movement cytometry utilizing SARS-CoV-2 NP-immobilized magnetic beads. A aggressive immunoassay was developed for detecting SARS-CoV-2 NP in addition to SARS-CoV-2 within the tradition fluid utilizing magnetic beads with immobilized anti-SARS-CoV-2 NP antibodies. Selectivity assessments have been carried out throughout the aggressive immunoassay for SARS-CoV, MERS-CoV, and CoV pressure 229E within the tradition fluid.

Discount in Nesfatin-1 Ranges within the Cerebrospinal Fluid and Elevated Nigrostriatal Degeneration Following Ventricular Administration of Anti-nesfatin-1 Antibody in Mice

Nesfatin-1 is one among a number of brain-gut peptides which have a detailed relationship with the central dopaminergic system. Our earlier research have proven that nesfatin-1 is able to defending nigral dopaminergic neurons towards 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. A current research additionally revealed a diminished blood degree of nesfatin-1 in sufferers with Parkinson’s illness (PD). The present research was designed to analyze whether or not diminished nesfatin-1 in cerebrospinal fluid (CSF) induces nigrostriatal system degeneration.

An intra-cerebroventricular (ICV) injection approach was used to manage anti-nesfatin-1 antibody straight into the lateral ventricle of the mind. Enzyme-linked immunosorbent assay (ELISA) outcomes confirmed that ICV injection of anti-nesfatin-1 antibody into the lateral ventricle of the mind as soon as day by day for two weeks precipitated a major discount in nesfatin-1 ranges within the CSF (93.1%).

Remedy with anti-nesfatin-1 antibody resulted in a considerable loss (23%) of TH-positive (TH+) dopaminergic neurons within the substantia nigra pars compacta (SNpc), as proven by immunofluorescence staining, a depletion in dopamine and its metabolites within the striatum detected by high-performance liquid chromatography (HPLC), and apparent nuclear shrinkage and mitochondrial lesions in dopaminergic neurons within the SNpc detected by transmission electron microscopy (TEM).

Moreover, the outcomes from our Western blot and ELISA experiments demonstrated that anti-nesfatin-1 antibody injection induced an upregulation of caspase-Three activation, elevated the expression of p-ERK, and elevated brain-derived neurotrophic issue (BDNF) ranges within the SNpc. Taken collectively, these observations recommend that diminished nesfatin-1 within the mind could induce nigrostriatal dopaminergic system degeneration; this impact could also be mediated by way of mitochondrial dysfunction-related apoptosis. Our information help a task of nesfatin-1 in sustaining the conventional physiological perform of the nigrostriatal dopaminergic system.

Convergent antibody evolution and clonotype enlargement following influenza virus vaccination

Current advances in high-throughput single cell sequencing have opened up new avenues into the investigation of B cell receptor (BCR) repertoires. On this research, PBMCs have been collected from 17 human contributors vaccinated with the split-inactivated influenza virus vaccine throughout the 2016-2017 influenza season. A mix of Immune Repertoire Seize (IRCTM) expertise and IgG sequencing was carried out on ~7,800 plasmablast (PB) cells and preferential IgG heavy-light chain pairings have been investigated. In some contributors, a single expanded clonotype accounted for ~22% of their PB BCR repertoire.

Roughly 60% (10/17) of contributors skilled convergent evolution, possessing public PBs that have been elicited independently in a number of contributors. Binding profiles of 1 non-public and three public PBs confirmed they have been all subtype-specific, cross-reactive hemagglutinin (HA) head-directed antibodies.

Anti-RANKL Neutralizing Antibody

100874-2 100 µg
EUR 460
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-VISTA Neutralizing Antibody

101293 100 µg
EUR 450
Description: This human monoclonal antibody recognizes human V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA), and neutralizes its interaction with VSIG3 (also called IGSF11). VISTA is also known as B7-H5 or VSIR (GenBank Accession No. NM_022153). VSIG3 is a ligand involved in cell adhesion as a VISTA binding partner. This neutralizing antibody has been functionally tested using the VSIG-3:VISTA [Biotinylated] Inhibitor Screening Assay Kit (BPS Bioscience #79782).

Anti-PCSK9 Neutralizing Antibody

71207 50 µg
EUR 555
Description: Neutralizing recombinant human antibody (IgG1) recognizing the LDLR binding region of human PCSK9.

Anti-TIGIT Neutralizing Antibody

71340 100 µg
EUR 565
Description: Human Anti-TIGIT neutralizing antibody recognizing the TIGIT binding region on immune cells.

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)

BCA-M43 100ug
EUR 2354
Description: Anti-BCMA Neutralizing Antibody, is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with BCMA.

Anti-PD-1 Neutralizing Antibody

71120 100 µg
EUR 465
Description: Neutralizing recombinant murine/human chimeric antibody recognizing the PD-L1/PD-L2 binding region of human PD-1. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Anti-IL-17A Neutralizing Antibody

91015 100 µg
EUR 490
Description: Neutralizing recombinant human_x000D_chimeric antibody recognizing human IL-17A._x000D_This antibody has not been tested for crossreactivity_x000D_with other species.

Anti-β-Amyloid Neutralizing Antibody

71223 100 µg
EUR 465
Description: Purified, recombinant, humanized Anti-β-amyloid (IgG1) antibody, expressed in HEK293 cells. This antibody reacts with human β-amyloid and has not been tested for cross-reactivity with other species.

Anti-CTLA4 (CD152) Neutralizing Antibody

71212 100 µg
EUR 490
Description: Neutralizing recombinant human monoclonal antibody recognizing the extracellular domain of CTLA4 and blocking binding of CTLA4 to B7.1 and B7.2. This antibody recognizes human CTLA4 but does not bind to murine CTLA4. This antibody has not been tested for cross-reactivity with other species.

Interferon Beta Human Neutralizing, Antibody

GWB-A7C102 0.5 mg Ask for price

Anti- Interferon Beta Neutralizing Antibody

GWB-C275F9 0.1 mg Ask for price

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody

abx411283-02mg 0.2 mg
EUR 678

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody

abx411283-100g 100 µg Ask for price

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody

abx411283-25g 25 µg
EUR 487.5

Anti-PD-L1 (CD274) Neutralizing Antibody

71213 100 µg
EUR 505
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested.

Human Cells anti-COVID-19 S-IgM Neutralizing Antibody

DL99728A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgM Neutralizing Antibody

DL99728A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgA Neutralizing Antibody

DL99729A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgA Neutralizing Antibody

DL99729A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody (FITC)

abx411284-01mg 0.1 mg
EUR 610.8

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody (FITC)

abx411284-100g 100 µg
EUR 425

Anti-2019-nCoV Spike Neutralizing Antibody

E-AB-V1024-100uL 100uL
EUR 650
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody

E-AB-V1024-50uL 50uL
EUR 390
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody

E-AB-V1024-each each Ask for price
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody

E-AB-V1025-100uL 100uL
EUR 650
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody

E-AB-V1025-50uL 50uL
EUR 390
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody

E-AB-V1025-each each Ask for price
Description: Unconjugated

Human Cells anti-COVID-19 S-hIgG1 Neutralizing Antibody

DL99725A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-hIgG1 Neutralizing Antibody

DL99725A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

human anti-CPV neutralizing mAb

E4A09V04 50ug
EUR 255
Description: Available in various conjugation types.

human anti-FPV neutralizing mAb

E4A09V05 50ug
EUR 255
Description: Available in various conjugation types.

Anti-Enterovirus 71 VP1 Neutralizing Antibody

E-AB-V1081-100uL 100uL
EUR 200
Description: Unconjugated

Anti-Enterovirus 71 VP1 Neutralizing Antibody

E-AB-V1081-200uL 200uL
EUR 300
Description: Unconjugated

Anti-Enterovirus 71 VP1 Neutralizing Antibody

E-AB-V1081-500uL 500uL
EUR 465
Description: Unconjugated

Anti-Enterovirus 71 VP1 Neutralizing Antibody

E-AB-V1081-each each Ask for price
Description: Unconjugated

Anti-Enterovirus 71 VP4 Neutralizing Antibody

E-AB-V1082-100uL 100uL
EUR 200
Description: Unconjugated

Anti-Enterovirus 71 VP4 Neutralizing Antibody

E-AB-V1082-200uL 200uL
EUR 300
Description: Unconjugated

Anti-Enterovirus 71 VP4 Neutralizing Antibody

E-AB-V1082-500uL 500uL
EUR 465
Description: Unconjugated

Anti-Enterovirus 71 VP4 Neutralizing Antibody

E-AB-V1082-each each Ask for price
Description: Unconjugated

Anti-2019-nCoV S-IgM Neutralizing Antibody

E-AB-V1026-100uL 100uL
EUR 425
Description: Unconjugated

Anti-2019-nCoV S-IgM Neutralizing Antibody

E-AB-V1026-200uL 200uL
EUR 750
Description: Unconjugated

Anti-2019-nCoV S-IgM Neutralizing Antibody

E-AB-V1026-50uL 50uL
EUR 260
Description: Unconjugated

Anti-2019-nCoV S-IgM Neutralizing Antibody

E-AB-V1026-each each Ask for price
Description: Unconjugated

Anti-2019-nCoV S-IgA Neutralizing Antibody

E-AB-V1027-100uL 100uL
EUR 425
Description: Unconjugated

Anti-2019-nCoV S-IgA Neutralizing Antibody

E-AB-V1027-200uL 200uL
EUR 750
Description: Unconjugated

Anti-2019-nCoV S-IgA Neutralizing Antibody

E-AB-V1027-50uL 50uL
EUR 260
Description: Unconjugated

Anti-2019-nCoV S-IgA Neutralizing Antibody

E-AB-V1027-each each Ask for price
Description: Unconjugated

Anti-COVID-19 S-IgM Neutralizing Antibody

E38A9973 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-IgA Neutralizing Antibody

E38A9974 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-2019-nCoV S-hIgG1 Neutralizing Antibody

E-AB-V1021-100uL 100uL
EUR 425
Description: Unconjugated

Anti-2019-nCoV S-hIgG1 Neutralizing Antibody

E-AB-V1021-200uL 200uL
EUR 750
Description: Unconjugated

Anti-2019-nCoV S-hIgG1 Neutralizing Antibody

E-AB-V1021-50uL 50uL
EUR 260
Description: Unconjugated

Anti-2019-nCoV S-hIgG1 Neutralizing Antibody

E-AB-V1021-each each Ask for price
Description: Unconjugated

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody

E-AB-V1022-100uL 100uL
EUR 425
Description: Unconjugated

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody

E-AB-V1022-200uL 200uL
EUR 750
Description: Unconjugated

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody

E-AB-V1022-50uL 50uL
EUR 260
Description: Unconjugated

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody

E-AB-V1022-each each Ask for price
Description: Unconjugated

Anti-2019-nCoV S-cIgG1 Neutralizing Antibody

E-AB-V1023-100uL 100uL
EUR 425
Description: Unconjugated

Anti-2019-nCoV S-cIgG1 Neutralizing Antibody

E-AB-V1023-200uL 200uL
EUR 750
Description: Unconjugated

Anti-2019-nCoV S-cIgG1 Neutralizing Antibody

E-AB-V1023-50uL 50uL
EUR 260
Description: Unconjugated

Anti-2019-nCoV S-cIgG1 Neutralizing Antibody

E-AB-V1023-each each Ask for price
Description: Unconjugated

Anti-COVID-19 S-hIgG1 Neutralizing Antibody

E38A9970 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-mIgG1 Neutralizing Antibody

E38A9971 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-cIgG1 Neutralizing Antibody

E38A9972 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Human SARS-CoV-2 Neutralizing Antibody ELISA Kit

abx365044-100g 100 µg
EUR 618.75

Human SARS-CoV-2 Neutralizing Antibody ELISA Kit

abx365086-100g 100 µg
EUR 618.75

human anti-FPV/CPV neutralizing mAb

E409C40-h100 100μL
EUR 395
Description: Available in various conjugation types.

Interferon alpha Neutralizing Antibody

20-abx137013
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 1 mg

Anti-NGF (Nerve Growth Factor) Neutralizing Antibody

100436-1 50 µg
EUR 355
Description: Anti-NGF Neutralizing Recombinant Human antibody. This_x000D_ antibody has not been tested for crossreactivity_x000D_ with other species.

Anti-NGF (Nerve Growth Factor) Neutralizing Antibody

100436-2 100 µg
EUR 490
Description: Anti-NGF Neutralizing Recombinant Human antibody. This_x000D_ antibody has not been tested for crossreactivity_x000D_ with other species.

Anti-PD-1 Neutralizing Antibody, Biotin-labeled

71215 100 µg
EUR 510
Description: Purified, recombinant, human anti-PD-1 (IgG1) antibody with C-terminal Avitag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Anti-2019-nCoV S-IgM Neutralizing Antibody (8A5)

EPT006 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-IgA Neutralizing Antibody (8A5)

EPT018 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)

SAD-S35 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Anti-PD-L1 Neutralizing Antibody, Biotin-labeled

71214 100 µg
EUR 510
Description: Purified, recombinant, chimeric murine/human anti-PD-L1 (IgG1) antibody with C-terminal Avi-tag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody reacts with human PD-L1 and cross-reacts with mouse PD-L1. It has not been tested for cross-reactivity with other species.

Anti-2019-nCoV S-hIgG1 Neutralizing Antibody (8A5)

EPT031 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody (8A5)

EPT084 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-cIgG1 Neutralizing Antibody (8A5)

EPT085 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180)

SPD-M180 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.98 μg/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. EP-105).Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Enterovirus 71 VP4 Neutralizing Antibody

abx201328-100l 100 µl
EUR 350

Enterovirus 71 VP4 Neutralizing Antibody

abx201328-50l 50 µl
EUR 275

Anti-PCSK9 Neutralizing Antibody, (IgG1) Biotin-labeled

71216 50 µg
EUR 530
Description: Purified recombinant human_x000D_anti-PCSK9 (IgG1) antibody with a C-terminal_x000D_Avi-tag, expressed in HEK293 cells. Purified_x000D_antibody was enzymatically biotinylated using_x000D_AviTag™ technology. This antibody reacts with_x000D_human PCSK9 and has not been tested for_x000D_cross-reactivity with other species.

Anti-PCSK9 Neutralizing Antibody, (IgG4) Biotin-labeled

71217 50 µg
EUR 515
Description: Purified recombinant human_x000D_anti-PCSK9 (IgG4) antibody with a C-terminal_x000D_Avi-tag, expressed in HEK293 cells. Purified_x000D_antibody was enzymatically biotinylated using_x000D_AviTag™ technology. This protein reacts with_x000D_human PCSK9 and has not been tested for_x000D_cross-reactivity with other species.

Denosumab Neutralizing Antibody ELISA Kit

abx395211-50g 50 µg
EUR 1937.5

Mouse anti-COVID-19 S-mIgG1 Neutralizing Antibody

DL99726A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Mouse anti-COVID-19 S-mIgG1 Neutralizing Antibody

DL99726A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

SARS-CoV-2 Spike Neutralizing Antibody

abx229977-100g 100 µg
EUR 325

SARS-CoV-2 Spike Neutralizing Antibody

abx229978-100g 100 µg
EUR 325

SARS-CoV-2 Spike Neutralizing Antibody

abx229979-100g 100 µg
EUR 325

SARS-CoV-2 Spike Neutralizing Antibody

abx229980-100g 100 µg
EUR 425

SARS-CoV-2 Spike Neutralizing Antibody

abx229981-100g 100 µg
EUR 425

SARS-CoV-2 Spike Neutralizing Antibody

abx229982-100g 100 µg
EUR 325

SARS-CoV-2 Spike Neutralizing Antibody

abx229983-100g 100 µg
EUR 325

Cynomolgus anti-COVID-19 S-cIgG1 Neutralizing Antibody

DL99727A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Cynomolgus anti-COVID-19 S-cIgG1 Neutralizing Antibody

DL99727A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Monoclonal NGF/proNGF Neutralizing Antibody Antibody

AMM06679G 0.05mg
EUR 633.6
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E

SARS-CoV-2 Neutralizing Antibody ELISA Kit

CSB-EL33243HU 96Т
EUR 595
Description: serum, plasma

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122)

S1N-M122 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529).

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122)

SPD-M162 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293).

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgA1 (AM122)

SPD-M58P1 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgA1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgA1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein.

HIV p24 Neutralizing Monoclonal Antibody

0222-PP-001 110ug
EUR 500
Description: Rabbit monoclonal antibody

Cytomegalovirus gH Antibody (late neutralizing antigen)

GWB-4068DD 0.2 mg Ask for price

Cytomegalovirus gB Antibody (late neutralizing antigen)

GWB-7F0460 0.2 mg Ask for price

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128)

SPD-M128 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (SPD-M128) is a chimeric monoclonal antibody combining the constant domains of the human IgG1 molecule with mouse variable regions. Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Rabbit anti-LukAB pAb (neutralizing)

0313-001 500ug
EUR 350
Description: Protein A purified neutralizing rabbit polyclonal antibody reactive to S. aureus LukA and LukB

Anti-SARS-CoV-2 Spike RBD (CB6 biosimilar) Neutralizing Antibody

E-AB-V1028-100uL 100uL
EUR 425
Description: Unconjugated

Anti-SARS-CoV-2 Spike RBD (CB6 biosimilar) Neutralizing Antibody

E-AB-V1028-200uL 200uL
EUR 750
Description: Unconjugated

Anti-SARS-CoV-2 Spike RBD (CB6 biosimilar) Neutralizing Antibody

E-AB-V1028-50uL 50uL
EUR 260
Description: Unconjugated

Anti-SARS-CoV-2 Spike RBD (CB6 biosimilar) Neutralizing Antibody

E-AB-V1028-each each Ask for price
Description: Unconjugated

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122)

SCT-M369 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122) (SCT-M369), originally from mouse immunized with recombinant SARS-CoV-2 Spike RBD protein, is recombinantly expressed from HEK293 cells.

Spike Neutralizing Antibody (Clone G10xA1) (SARS-CoV-2)

101326 100 µg
EUR 600
Description: This monoclonal antibody recognizes the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2 [Table of Variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2):ACE2 Inhibitor Screening Colorimetric Assay Kit (BPS Bioscience #78339).

Spike Neutralizing Antibody (Clone G10xA5) (SARS-CoV-2)

101327 100 µg
EUR 600
Description: This monoclonal antibody recognizes the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2 [Table of Variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit (BPS Bioscience, #78339).

Anti- Platelet Derived Growth Factor-AB (PDGF-AB) Neutralizing Antibody

GWB-F29665 1 mg Ask for price

Cytomegalovirus gB Antibody (Late neutralizing antigen) (FITC)

GWB-25626C 0.1 mg Ask for price

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-2)

100792 100 µg
EUR 460
Description: Recombinant human monoclonal (clone 414-2) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-1)

100793 100 µg
EUR 485
Description: Recombinant human monoclonal (clone 414-1) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Collectively, this high-resolution antibody repertoire evaluation demonstrated the influence evolution can have on BCRs in response to influenza virus vaccination, which may information future common influenza prophylactic approaches.

 

Leave a Reply

Your email address will not be published. Required fields are marked *